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The Ser52Pro variant of transthyretin (TTR) produces aggressive,
highly penetrant, autosomal-dominant systemic amyloidosis in
persons heterozygous for the causative mutation. Together with
a minor quantity of full-length wild-type and variant TTR, the main
component of the ex vivo fibrils was the residue 49-127 fragment
of the TTR variant, the portion of the TTR sequence that previously
has been reported to be the principal constituent of type A, cardiac
amyloid fibrils formed from wild-type TTR and other TTR variants
[Bergstrom J, et al. (2005) J Pathol 206(2):224–232]. This specific
truncation of Ser52Pro TTR was generated readily in vitro by lim-
ited proteolysis. In physiological conditions and under agitation
the residue 49-127 proteolytic fragment rapidly and completely
self-aggregates into typical amyloid fibrils. The remarkable suscep-
tibility to such cleavage is likely caused by localized destabilization
of the β-turn linking strands C and D caused by loss of the wild-
type hydrogen-bonding network between the side chains of resi-
dues Ser52, Glu54, Ser50, and a water molecule, as revealed by the
high-resolution crystallographic structure of Ser52Pro TTR. We
thus provide a structural basis for the recently hypothesized, cru-
cial pathogenic role of proteolytic cleavage in TTR amyloid fibrillo-
genesis. Binding of the natural ligands thyroxine or retinol-binding
protein (RBP) by Ser52Pro variant TTR stabilizes the native tetra-
meric assembly, but neither protected the variant from prote-
olysis. However, binding of RBP, but not thyroxine, inhibited
subsequent fibrillogenesis.
misfolding | protein aggregation
Amyloidosis is caused by extracellular accumulation of ab-normal protein fibrils in various tissues throughout the body
(1). Hereditary systemic amyloidosis is a variably penetrant
autosomal dominant condition caused by mutations encoding
usually single-residue substitutions in certain globular proteins,
including transthyretin (TTR), apolipoprotein-AI, fibrinogen A
α-chain (2), gelsolin, lysozyme, cystatin C, and β2-microglobulin
(3). Individuals heterozygous for the causative mutated genes
produce variant proteins that are less stable than their wild-type
counterparts and consequently have a propensity to misfold and
then aggregate in the characteristic amyloid fibril conformation and
deposit in the tissues. TTR variants, encoded by more than 100
different amyloidogenic mutations (http://amyloidosismutations.
com/attr.html), are by far the most common cause of hereditary
amyloidosis, although there are only ∼10,000 cases worldwide.
Elucidation of the mechanism of amyloidogenic conversion
of TTR has been challenging and hitherto has not been revealed
by any obvious feature of the native protein structure despite
very high-resolution crystallography of the wild-type and several
amyloidogenic variants (4). The native tetrameric assemblies of
all amyloidogenic TTR variants studied so far are less stable in
vitro than wild-type TTR, whereas the Thr119Met variant is more
stable and is known to protect carriers of amyloidogenic muta-
tions from developing TTR amyloidosis (5). Therefore it is widely
accepted that tetramer dissociation and partial denaturation of re-
leased monomers is the crucial and rate-limiting prerequisite for the
formation of TTR amyloid fibrils (2). However, there is no direct
supportive evidence for this mechanism in vivo, and a key role for
posttranslational modifications of TTR, including partial pro-
teolysis has been debated extensively (6).
In addition to full-length TTR monomers, Lundgren’s group
identified the residue 49-127 fragment, generated by proteolytic
cleavage of the peptide bond Lys48–Thr49 (7), as the main
fragment present in ex vivo TTR amyloid fibrils. The protease
responsible has not yet been identified, but the highly specific
cleavage suggests that it could be a trypsin-like serine protease.
Meanwhile Westermark and collaborators have elegantly char-
acterized the constituents of TTR amyloid fibrils extracted from
cardiac amyloid deposits and adipose tissue, identifying two clearly
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distinct categories (8, 9). TypeA fibrils contain a high proportion of
truncated species that are not found in type B fibrils, which are
composed almost entirely of full-length TTR (8). The presence of
cleaved fragments apparently is not influenced by the nature or the
position of the amino acid substitution (8). Rather, it correlates
with the abundance of the cardiac amyloid deposits (10), with in-
creased patient age, and with late-onset disease, being most com-
mon in persons with senile systemic amyloidosis caused by wild-
type, not variant, TTR. The possible pathogenic role of proteolytic
cleavage is suggested further by the clinical course in persons with
hereditary TTR amyloidosis who undergo liver transplantation to
replace their variant TTR production with wild-type TTR. Indi-
viduals with type A fibrils in their cardiac deposits have a notably
poorer outcome, often with rapidly progressive cardiac involve-
ment (11).
Here we report a large kindred in which affected individuals
carrying the mutation encoding Ser52Pro variant TTR developed
unusually early-onset, aggressive, and fatal systemic amyloidosis.
Rapidly progressive amyloid polyneuropathy, soon followed by
symptomatic cardiac amyloidosis, developed in the third decade,
typically leading to death within 5 y. We now have fully char-
acterized the native structure of the variant and the composition
of the ex vivo amyloid fibrils, which contain abundant truncated
TTR cleaved at the C terminus of residue 48. This specific cleavage
was remarkably reproduced by limited proteolysis of the isolated
recombinant variant TTR in vitro, and we have established that,
once released from the native tetrameric protein, the polypeptide
49-127 rapidly self-aggregates into genuine amyloid fibrils.
Results
Hereditary Amyloidosis Phenotype. The proband (Fig. S1A, III-2)
presented at age 30 y with autonomic dysfunction, peripheral
neuropathy, euthyroid multinodular goiter, and sicca syndrome.
A needle biopsy of the thyroid contained extensive TTR amyloid
deposits, and the causative mutation encoding the Ser52Pro
TTR variant was detected by DNA sequencing. 123I-serum am-
yloid P component (SAP) scintigraphy (12) demonstrated sub-
stantial visceral amyloidosis affecting the spleen, liver, kidneys,
and adrenal glands. Echocardiography and subsequent cardiac
angiography demonstrated an infiltrative restrictive cardiomy-
opathy with well-preserved ventricular function, and there were
abundant TTR amyloid deposits in an endomyocardial biopsy.
He underwent liver transplantation in an attempt to reduce
abundance of the amyloidogenic variant, but amyloidosis nev-
ertheless progressed rapidly, and he died 5 mo later with cardiac
failure and progressive neuropathy. The proband’s mother (II-1)
died at age 34 y from a progressive neuromuscular disorder, and
extensive systemic amyloidosis was discovered at post mortem.
The clinical picture in subjects II-3 and II-5 was consistent with
neuropathic systemic amyloidosis, but no histological confirmation
was available. The maternal uncle of the propositus (II-3) was
diagnosed as paraplegic before his death at age 42 y in renal
failure. Subject II-5 developed thyromegaly from about age 20 y
and died at age 30 y from a neuromuscular disease with a pre-
sumptive diagnosis of multiple sclerosis. SAP scintigraphy in the
proband’s brother (III-3) at age 28 y showed extensive amyloid in
the spleen, kidneys, and adrenal glands, similar to the propositus.
He developed amyloid polyneuropathy 1 y later and died with
progressive amyloidosis, including severe cardiac involvement,
3 mo after liver transplantation. The third brother does not carry
the TTR mutation and remains asymptomatic. Two cousins died
before age 40 y with a similar pattern of disease but including
clinically significant leptomeningeal TTR amyloid deposits. One
of these subjects underwent liver transplantation when he had
only the very earliest symptoms of neuropathy and no definite
cardiac amyloid deposition, but he died 8 y later having de-
veloped profound neuropathy, severe cardiac amyloidosis, and
dementia. The clinical phenotype in this kindred is among the
most severe ever described in TTR-related amyloidosis.
DNA Sequencing. The proband, his affected brother, and the two
affected cousins were heterozygotes for a single-point mutation
in exon 3 of the TTR gene, encoding substitution of a proline
(codon CCT) for serine (codon TCT) at residue 52 of the mature
TTR protein (Fig. S1B). The father, unaffected brother, and
unaffected cousins were homozygous for the wild-type sequence.
Amyloid Fibril Protein Typing. Immunohistochemical staining of
the cardiac biopsy from the propositus identified TTR as the
amyloid fibril protein (Fig. S1C), and the deposits also stained for
SAP, the universal nonfibrillar component of all human amyloid.
Analysis of ex Vivo Fibrils. Ex vivo amyloid fibrils were isolated
from the spleen of the propositus removed during liver trans-
plantation and were separated by SDS/PAGE (Fig. 1 A and B)
for further proteomic analysis. The mass mapping analysis of the
tryptic peptides from bands 1 and 2 in the gel are shown in Fig.
1C. The MALDI-MS spectrum of band 1 showed the presence of
several mass signals corresponding to TTR tryptic peptides lead-
ing to high protein-sequence coverage. In particular, the mass
signal at m/z 3,150.57 was assigned to the tryptic peptide 49-76
carrying the Ser-to-Pro amino acid substitution. A small signal at
m/z 3,140.54 corresponding to the wild-type peptide was detected
also. LC-MS/MS analysis of tryptic peptides from band 1 showed
that both the wild-type and Ser52Pro full-length TTR were pres-
ent with two mass signals at m/z 819.8 and 823.0 corresponding
Fig. 1. Ex vivo amyloid fibrils. (A) Transmission
electron microscopy of amyloid fibrils extracted
from spleen. (Direct magnification: 230,000×; scale
bar, 100 nm.) (B) SDS 15% PAGE under reducing
conditions. Lane a: marker proteins (14.4, 20.1, 30.0,
45.0, 66.0, and 97.0 kDa, respectively); lane b: 0.5 μg
recombinant Ser52Pro TTR; lane c: 60 μg ex vivo
amyloid fibrils from spleen. 1 and 2 indicate bands
subjected to mass mapping analysis. (C) Tryptic pep-
tides obtained by digestion of SDS/PAGE bands were
analyzed by MALDI-MS and nano-LC MS-MS. MH+
monoisotopic values are reported for each peptide;
asterisks indicate the presence of the Ser52Pro sub-
stitution. Cysteine is carbamidomethylated.
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to the triply charged wild-type and variant peptides 49-70, re-
spectively. This assignment was confirmed by the MS/MS spectra of
the two precursor ions. In contrast, MS analysis of band 2 showed
only a single protein species, corresponding to the C-terminal
fragment of the variant TTR generated by cleavage at residue
Lys48. Five cycles of N-terminal Edman sequencing of band 2
yielded Thr-Ser-Glu-Pro-Gly, i.e., residues 49–53 of variant TTR,
unequivocally confirming the presence of proline at only position
52 (Fig. S2).
Authenticity and Stability of Recombinant TTR Proteins.The subunits
of recombinant wild-type and Ser52Pro variant TTR proteins
had molecular masses of 13,892.2 ± 0.9 Da and 13,902.1 ± 1.5 Da,
respectively, corresponding to the expected theoretical mass
values of 13,892.6 Da and 13,902.7 Da, including the additional
N-terminal methionine residue, Met0. Correct assembly of the
subunits into native homotetrameric wild-type and variant TTR
was confirmed by both size-exclusion chromatography and native
mass spectrometry, and these intact proteins bound the natural
ligand, thyroxine, normally, showing the same IC50 with mds84
and Tafamidis (13, 14) as native wild-type TTR isolated from
normal human serum (Table S1). However, the guanidine thio-
cyanate (Gdn-SCN)–mediated transition from folded tetramer
to unfolded monomers (Fig. S3) (5) showed that the native tet-
rameric Ser52Pro variant TTR was destabilized significantly, by
2.3 kcal/mol, compared with the wild-type protein, with a mid-
point concentration of Gdn-SCN (Cm) shifting from mean (SD)
of 1.03 (0.02) M for the wild type to 0.8 (0.06) M for the variant
(n = 3) (Table S2).
Limited Proteolysis of Recombinant Wild-Type and Variant TTR.
Proteolysis at a very low enzyme:substrate ratio is a powerful
and highly discriminating approach for comparing the most
flexible and solvent-exposed sites and thus monitoring focal
stability in the surface topology of native globular proteins. It
revealed a surprisingly dramatic difference between wild-type
and Ser52Pro variant TTR, the former being completely re-
sistant to cleavage even after long incubation or increased pro-
tease concentration, whereas the latter was proteolyzed rapidly.
Fig. 2A shows the electrophoretic pattern of the product of
trypsin digestion. After 1 h of incubation the variant TTR re-
leased three main polypeptides which we identified by MALDI-
MS analysis of the corresponding electroeluted bands as peptides
16-127 (purple in Fig. 2), 49-127 (green in Fig. 2), and 81-127
(red in Fig. 2), respectively. In the same lane of the gel the band
of the undigested monomer of Ser52Pro TTR was also present
(Fig. 2A).
Consistent with the protease resistance of wild-type TTR, and
in sharp contrast to the exquisite sensitivity of the Ser52Pro
variant, none of the other recombinant amyloidogenic TTR
variant proteins which we tested (Val30Met, Leu55Pro, and
Val122Ile) was cleaved at all under the conditions used (Fig. S4).
In this experiment we monitored the proteolytic cleavage in the
early phase of incubation up to 2 h, thus showing that the peptide
49-127 (green box in Fig. S4) is formed already at 3 min of trypsin
exposure. The peptide 81-127 (red box in Fig. S4) is most likely
a later product derived from a secondary proteolytic cleavage, as
are other minor unidentified lower molecular weight fragments.
TTR Cleavage and Fibril Formation. Like wild-type TTR and all
other amyloidogenic TTR variants previously tested, the full-
length Ser52Pro variant did not form amyloid fibrils in vitro
when stirred in solution at physiological pH and ionic strength
(Fig. 3A). In contrast, when trypsin was added to the native
Ser52Pro TTR solution in PBS at 37 °C while the solution was
stirred at 900 rpm, thioflavin T (ThT) fluorescence increased
very rapidly (Fig. 3A). Fibrillogenesis of this variant under physi-
ological conditions was strictly dependent on both proteolytic
cleavage and stirring, and the main component of this fibrillar
and insoluble material was the same residue 49-127 fragment
(Fig. 3B, lane c) identified in the natural fibrils (Fig. 3B, lane d).
The fibrils formed by residue 49-127 variant TTR peptide in vitro
showed the pathognomonic amyloid green birefringence under
polarized light after staining with Congo red. Transmission elec-
tron microscopy showed that the aggregated TTR was almost
entirely fibrillar, with minimal amorphous material (Fig. 3C),
indicating much more efficient fibrillar conversion than previously
reported for in vitro TTR aggregation (15). Atomic force mi-
croscopy (Fig. 3D) confirmed the fibrillar ultrastructure. The
diffraction pattern obtained from partially aligned Ser52Pro TTR
variant amyloid fibrils showed diffraction signals at 4.7 Å and
9.5 Å (Fig. 3E), consistent with the cross-β structure previously
reported for many different types of amyloid fibrils, including
Val30Met TTR (16). Although the fibrils were difficult to orient,
probably because of their tangled nature (Fig. 3C), the diffrac-
tion pattern shows increased intensity on the vertical axis com-
pared with horizontal axes supporting the cross-β arrangement
whereby β-strands are hydrogen bonded along the length of the
fibril with a regular 4.7-Å distance between them. The side chains
are accommodated between the β-sheets that are associated with
a distance of ∼9.5 Å. In addition to the cross-β signals, a strong
reflection at 18 Å was observed on the equator of the pattern;
this signal may arise from the association of protofilaments within
the fibrils.
Despite the intensely fibrillogenic nature of the residue 49-127
fragment of Ser52Pro TTR, addition of the fibrils formed by this
polypeptide did not seed amyloid fibril formation by either
native intact Ser52Pro TTR or wild-type TTR in physiological
buffer (Fig. S5).
3D Crystal Structures. Both wild-type and Ser52Pro TTR crystal-
lized in the commonly reported orthorhombic crystal form
(space group P21212) that contains a dimer of TTR subunits in
the asymmetric unit. The structures are very similar, and back-
bone atoms for 221 residues in which the electron density is good
superposed with an rmsd of 0.42 Å. The regions showing the
Fig. 2. Limited trypsin proteolysis of wild-type and Ser52Pro TTR. (A) SDS
(15%) PAGE under reducing conditions of wild-type and Ser52Pro TTR after
incubation at 37 °C with trypsin at an enzyme:substrate ratio of 1:200 for the
times shown. Wild-type TTR alone (a) or with trypsin (b), Ser52Pro TTR alone
(c) or with trypsin (d). The three main polypeptides released from Ser52Pro
TTR after 1 h of digestion are highlighted with purple, green, and red boxes.
(B) MALDI-MS spectra of the fragments electroeluted from the bands shown
in A and acquired in linear mode.
Mangione et al. PNAS | January 28, 2014 | vol. 111 | no. 4 | 1541
M
ED
IC
A
L
SC
IE
N
CE
S
largest differences are displayed in Fig. 4A. The region 19-23 of
molecule A may be of particular note, because a hydrogen bond
between Ala19 CO and Tyr114 NH of a symmetry-related sub-
unit is a contributor to the limited bonding that stabilizes the
tetramer. The position of Ala19 CO differs by more than 1.1 Å in
the two structures, suggesting some disturbance of the tetramer,
but the hydrogen bond with Tyr114 is sustained. The proline
substitution was modeled readily into the electron density for the
β-turn at position 52 (Fig. 4B). Crucially, however, the hydrogen-
bonding network involving Ser52, Glu54, and Ser50 in both TTR
subunits in the wild-type structure, and including a water mole-
cule in subunit A, is modified in the variant. In the absence
of Ser52, its hydrogen-bonding partner, the Glu54 carboxylate,
rotates by 90° and makes new interactions with Lys15 or His56;
no interaction can exist between Pro52 and the Ser50 side chain.
Only three hydrogen bonds ≤3 Å in length (Ser50 CO and Gly53
NH; Ser50 NH and Glu54 CO; and Ser50 OG and Glu54 CO)
remain in the turn of the variant protein, compared with five
in wild-type TTR. The loss of two hydrogen bonds would be
expected to destabilize the turn and the associated C and D
strands substantially. Displacement of this loop region has been
proposed as the final common pathway for fibrillogenesis in a
selection of amyloidogenic TTR variants by exposing edge strands
of the core β-structure of the protein (17). Such movements
certainly would increase the accessibility of Lys48 to proteolytic
cleavage.
The mechanism of the observed tetramer destabilization cannot
be determined directly from the crystal structure presented, but
it is reasonable to suppose that the observed loop I and II
changes in the crystal structure of Ser52Pro TTR, situated at or
close to subunit interfaces, may be vestiges of a conformer
population in solution where more extreme structural fluctua-
tions exist. Transient exposure of isolated subunits, as occurs in
subunit exchange (18), could provide a context in which the lack
of subunit-stabilizing forces of the tetramer allows full expression
of the destabilizing influence of the Pro52 substitution. For the
Ser52Pro variant the cleavage of the 48-49 peptide bond should
not result in the dissociation of the 1-48 peptide, because many
of the bonding interactions remain in place. However, the NH of
the 48-49 peptide bond hydrogen bonds to Val28 CO of strand B
close to turn I. Although this hydrogen bond might be sustained
by the new N terminus generated by cleavage, the separation of
this N-terminal end from the new carboxylate of Lys48 must
widen from 1.2 to at least 2.8 Å and promote displacement of
the CD turn. Departure of the 1-48 peptide caused by shear
forces in solution would remove important dimer–dimer inter-
action regions (19-23) and promote dissociation of the remaining
49-127 fragment.
Proteolysis of Ser52Pro TTR with Bound Ligands.Binding of Tafamidis
and mds84 (13, 14), which both enter the TTR inner channel, had
no significant effect on the products (Fig. 5A) or kinetics (Fig. 5B)
of trypsin digestion of Ser52Pro variant TTR. Epigallocatechin,
which binds to the outer molecular surface, similarly did not re-
duce the susceptibility of Ser52Pro TTR to proteolytic cleavage,
although the appearance of TTR oligomers prevented precise
quantification of full-length TTR, as previously reported (19).
Evidently these various, avidly bound ligands, do not protect the
susceptible TTR sequences despite their potent stabilization of
the native tetrameric assembly. Finally, we have tested the effect
of the two natural ligands of TTR, thyroxine and retinol-binding
protein (RBP) (Fig. S6), on the proteolysis of Ser52Pro TTR and
its fibrillogenesis (Fig. 6). Neither of the two interactors protected
Fig. 3. Fibrillogenesis of Ser52Pro TTR triggered by release of the residue
49-127 fragment. (A) Normalized ThT fluorescence emission from wild-type
TTR (black) and Ser52Pro TTR (red) fibrillogenesis in the presence (solid lines)
and absence (dotted lines) of trypsin 5 ng/μL. (B) SDS 15% PAGE under re-
ducing conditions. Lane a: marker proteins (14.4, 20.1, 30.0, 45.0, 66.0, and
97.0 kDa); lane b: recombinant Ser52Pro TTR; lane c: in vitro Ser52Pro fibrils;
lane d: ex vivo amyloid fibrils from spleen. (C) Negatively stained trans-
mission electron micrograph of Ser52Pro TTR amyloid fibrils generated in the
presence of trypsin and shaking. (Direct magnification: 175,000×; scale bar,
100 nm.) (D) Tapping mode atomic force microscopy image (height data) of
Ser52Pro TTR fibrils obtained as in A. Scan size: 2.0 μm; Z range: 10 nm. (E)
The X-ray fiber diffraction pattern collected from partially aligned amyloid
fibrils formed by Ser52Pro TTR (λ = 1.5417 Å; sample-to-detector distance =
100 nm; exposure time = 30 s) shows a reflection that is stronger on the
meridian at 4.7 Å. A reflection also is highlighted at 9.5 Å, and a well-oriented
signal is seen at 18 Å.
Fig. 4. 3D structure of wild-type and Ser52Pro TTR. (A) Crystal structures of
wild-type and Ser52Pro TTR were superposed by secondary structure
matching [gray-interpreted and presented by CCP4MG (27)] and show the
close similarity of the folds, Rmsd = 0.42Å over 221 residues. Regions of
greatest difference are highlighted in blue (Ser52Pro) and magenta (wild
type). The CD loops for one subunit of both proteins are shown in green. (B)
Stick diagram of the CD loop region (carbon is shown in green, oxygen in
red, and nitrogen in blue) for wild-type (Left) and Ser52Pro (Right) TTR
showing the diminished hydrogen-bonding network in the vicinity of the
proline substitution that may contribute to the enhanced susceptibility of
the variant to proteolytic cleavage at Lys48 (28). X-ray data statistics are
reported in Table S3.
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against the selective cleavage (Fig. 6, Inset), and binding of RBP,
but not thyroxine, totally inhibited fibrillogenesis. Our preliminary
mass spectrometry analysis confirms the capacity of RBP to retain
the cleaved monomer within a stabilized native tetramer.
Discussion
The Ser52Pro TTR variant causes devastating, rapidly progressive,
hereditary neuropathic systemic amyloidosis with extensive visceral
and cardiac involvement which is universally fatal in early- to
mid-adult life. Our present characterization of the structure
and properties of the Ser52Pro variant provide a compelling
biophysical explanation of this aggressive pathology.
The Ser52Pro substitution both destabilizes the native tetra-
mer assembly and makes the protein highly susceptible to a se-
lective, specific proteolytic cleavage at residue 48 to release the
C-terminal residue 49-127 fragment, which is potently amyloid
fibrillogenic. The 3D structure of the variant TTR shows no
gross structural changes affecting the accessibility of Lys48 that
would enhance sensitivity to proteases. The structural similarity
with the normal wild-type counterpart protein (4) explains the
failure of intracellular quality-control mechanisms to censor
the secretion of these pathogenic proteins. However, despite the
marked overall structural conservation (Fig. 4A), we observed
a modest difference in the 3D structure of Ser52Pro TTR
(Fig. 4B) that likely is responsible for its crucial sensitivity to
proteolytic cleavage.
The variant Pro52 residue is located in the type 1 β-turn that
connects β-strands C and D, and the dihedral angles of the wild-type
Ser52 residue enable substitution by proline without adjustment of
the main-chain path. However, the Ser52 side chain participates in
a hydrogen-bonding network across the turn in the wild-type pro-
tein. Loss of this network caused by the proline substitution almost
certainly destabilizes the turn and perturbs the adjacent strands,
increasing their flexibility, abrogating the protection against pro-
teolysis in the wild-type protein, and contributing to the significant
observed thermodynamic destabilization.
Exposure of the native Ser52Pro variant TTR tetramer to very
low-dose trypsin under physiological conditions rapidly gener-
ated the same residue 49-127 fragment that is found in ex vivo
TTR amyloid fibrils, specifically those designated as type A,
which are present in patients with other amyloidogenic TTR
variants and patients with senile systemic amyloidosis caused by
deposition of wild-type TTR (20). However, neither wild-type
TTR nor the other TTR variants we tested (Val30Met, Leu55-
Pro, and Val122Ile) were similarly cleaved in vitro, and thus they
are notably more stable to proteolysis. Nevertheless, it is plau-
sible that in in vivo conditions, in particular shear flow and
exposure to hydrophobic surfaces in the dynamic environment
of the interstitial space, may promote local structural desta-
bilization (21, 22) and enable proteolytic cleavage. Indeed
focal mechanical destabilization of the polypeptide chain is a
well-known mechanism for priming limited physiological pro-
teolytic cleavage in the homeostasis of hemostatic proteins. The
classic example of this mechano-enzymatic mechanism involves
the multimeric von Willebrand factor in which shear forces in-
duce a local destabilization and permit the proteolytic cleavage
by a specific metalloprotease (23).
Our identification, in the amyloid fibrils in the present pro-
positus, of full-length TTR monomers from both the wild-type
and variant proteins but the highly fibrillogenic residue 49-127
fragment from only the variant, strongly suggests that the native
tetrameric TTR variant, rather than already formed fibrils, is the
substrate for proteolytic cleavage in vivo. Furthermore our newly
established in vitro method of generating genuine TTR amyloid
fibrils after enzymatic cleavage suggests that proteolysis may be a
prefibrillar event, at least for this variant, because massive rapid
amyloid fibril formation proceeds as soon as the N-terminal
48-residue peptide is released. In contrast, the recombinant
residue 49-127 fragment produced by Mizuguchi et al. (24)
gave a very low yield of amyloid fibrils in vitro. This discrepancy
highlights aspects of the TTR amyloid pathway, suggesting that
the type of aggregate is strictly dependent on the structural
conformation of the precursor. Our finding that fibril formation
is much more efficient when the truncated amyloidogenic pre-
cursor is cleaved directly from the folded TTR molecule is
consistent with the early observation that the intermediate
capable of forming amyloid fibrils retains much of the secondary
and tertiary structure of native TTR (25).
In conclusion, the discovery of the peculiar proteolytic pro-
cessing of the Ser52Pro variant illuminates a potentially general
pathway of TTR amyloidogenesis dictated by the formation of
the residue 49-127 polypeptide. It will be interesting in the future
to investigate the possible presence of cleaved TTR or the residue
Fig. 5. Limited proteolysis of Ser52Pro TTR with bound ligands. (A) SDS 15%
PAGE under reducing conditions of Ser52Pro TTR alone in presence of DMSO
(a) or a fivefold molar excess of epigallocatechin (b), mds84 (c), or Tafamidis
(d) after incubation at 37 °C with trypsin at an enzyme:substrate ratio of
1:200 for the times shown. Marker proteins (14.4, 20.1, 30.0, 45.0, 66.0, and
97.0 kDa) and the nontreated Ser52Pro TTR (pretrypsin) are in the first two
lanes. (B) Kinetics of proteolytic cleavage of holo Ser52Pro TTR in presence of
DMSO (black), mds84 (green), or Tafamidis (red) monitored by density with
time of the intact monomeric TTR band (arrow in A).
Fig. 6. Effect of natural interactors, thyroxine and RBP, on proteolysis/
fibrillogenesis by Ser52Pro TTR. Normalized ThT fluorescence emission for
trypsin-dependent fibrillogenesis of Ser52Pro TTR alone (a) or in the pres-
ence of a twofold excess of thyroxine (b), a twofold excess of RBP (c), or RBP
alone (d). (Inset) SDS 15% PAGE under reducing conditions of fibrillogenesis
samples before and after 4 h of trypsin digestion. Marker proteins (14.4,
20.1, 30.0, 45.0, 66.0, and 97.0 kDa) are included.
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49-127 fragment in the circulation of patients and carriers of
this mutation. Furthermore, because ligands that potently sta-
bilize the native tetrameric assembly of TTR do not protect
Ser52Pro TTR against the amyloidogenic cleavage, additional
therapeutic approaches to inhibiting TTR amyloidogenesis may
be required. It is worth noting that thyroxine, the natural ligand
occupying the inner channel of the TTR tetramer, does not
prevent either proteolysis or fibril formation. In contrast, RBP,
although unable to protect from cleavage, is a very efficient in-
hibitor of fibrillogenesis. The different effects of thyroxine and
RBP on proteolysis and fibrillogenesis are consistent with a se-
quential two-phase process. The first phase comprises cleavage
of the 48-49 peptide bond but does not itself necessarily release
the truncated residue 49-127 polypeptide from the intact native
tetramer. In the second phase forces such as those generated by
fluid agitation (22) are sufficient to release the fragments with
consequent fibril formation. Thyroxine does not stabilize the
tetramer sufficiently to prevent fibrillogenesis, whereas the
binding of RBP is adequate to block the second phase, impeding
release of the fibrillogenic free fragment.
The discovery and characterization of these crucial steps in the
pathway of TTR amyloid fibrillogenesis could provide novel drug
discovery targets as well as offering insight into the mode of
action and potential efficacy of current approaches based on
drugs occupying the thyroxine-binding site.
Methods
Limited Proteolysis. Recombinant wild-type, Ser52Pro variant TTR, Val122Ile,
Val30Met, and Leu55Pro TTR, were individually digested at 1 mg/mL in PBS (pH
7.4) at 37 °C containing trypsin at an enzyme:substrate (wt/wt) ratio of 1:200.
At different times, aliquots of each incubation mixture were stopped by
adding PMSF to 1.5 mM, were boiled immediately in SDS sample buffer, and
were stored at −20 °C before SDS 15% PAGE was carried out under reducing
conditions. For proteomic characterization of the proteolytic fragments,
Coomassie Blue-stained bands were electroeluted, lyophilized, dissolved in
0.2% TFA, mixed with α-cyano-4-hydroxycinammic acid (5 mg/mL in acetoni-
trile, 0.2% TFA, 7:3, vol/vol), and left to air dry in a metallic sample plate
before linear MS analysis (Waters Micromass spectrometer). Horse heart
myoglobin was used for mass calibration.
The effect of trypsin also was tested at a 1:200 enzyme:substrate (wt/wt)
ratio in the presence of a fivefold molar excess of Tafamidis (14), mds84 (13),
and epigallocatechin (19), respectively.
Amyloid Fibrillogenesis. Samples of recombinant wild-type and Ser52Pro TTR,
100 μL at 1 mg/mL in PBS (pH 7.4) containing 10 μM ThT (26), were incubated
at 37 °C in Costar 96-well black-wall plates sealed with clear sealing film and
were subjected to 900 rpm double-orbital shaking. Bottom fluorescence was
recorded at 5-min intervals (BMG LABTECH FLUOstar Omega). After 1 h,
5 ng/μL of trypsin (Promega Trypsin Gold Mass Spectrometry Grade) or buffer
alone was added, and fluorescence was monitored in three or more replicate
test and control wells for the next 4 h. The data were normalized to the
signal plateau at ∼4 h after the initiation of each reaction. Sample processing
for microscopy analyses and fibrillogenesis assays in the presence of seeds,
thyroxine, or holo-RBP are described in SI Methods.
Other Methods. Histology, isolation, and chemical characterization of ex vivo
amyloid fibrils, DNA sequencing, recombinant TTR production, thyroxine dis-
placement assay, equilibrium denaturation, electron microscopy, atomic force
microscopy and X-ray fiber diffraction, X-ray crystal structure determination,
and native mass spectrometry analysis of the TTR–RBP complex are described in
SI Methods.
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